
100.9K
Downloads
72
Episodes
Written by expert consultants and clinical scientists currently practising in the UK, the BSH Guidelines provide up-to-date evidence-based guidance on the diagnosis and treatment of haematological diseases. Self accreditation Listen to two podcasts and earn one CPD point via self-accreditation Join our Guidelines Newsletter to be notified when new guidelines/good practice papers are published by going into your members account under MyBSH. Non members can email bshguidelines@b-s-h.org.uk to sign up for updates.
Episodes

Friday Apr 25, 2025
Lymphoma SIG Podcast 6 - Mycosis fungoides
Friday Apr 25, 2025
Friday Apr 25, 2025
Dr Duncan Murray discusses mycosis fungoides and sezary syndrome.
Dr Murray completed his PhD at the University of Birmingham, looking at the interaction between the immune system and malignant T cells in skin lymphoma.
He finds the interaction between a "good" and "bad" T cell fascinating. He has used multiple single-cell laboratory techniques to tease apart the two populations (including V-beta antibodies, single-cell T-cell receptor (TCR) and ribonucleic acid (RNA) sequencing and mass cytometry).
Skin lymphoma is an unusual disease in that key determinants of the patient's outcome sit very close together. Both anatomically and in phenotype. His current work focuses on what we can learn from high-dimensional single-cell data and the bioinformatic process to assist this.

Wednesday Apr 23, 2025
Lymphoma SIG Podcast 5 - T-cell lymphomas
Wednesday Apr 23, 2025
Wednesday Apr 23, 2025
Dr Matthew Ahearne is a consultant haematologist at University Hospitals of Leicester NHS Trust. His main clinical and research focus is on T-cell lymphomas.
Dr Ahearne is Deputy Chair of the National Cancer Research Institute (NCRI) T-cell lymphoma working group and an NCRI Lymphoma Science sub-group member.

Friday Apr 11, 2025
Friday Apr 11, 2025
Dr Sridhar Chaganti discusses the current management of post-transplant lymphoproliferative disorder (PTLD), including subtypes, prognostic factors and the current treatment options.
He explores the role of immunotherapy, cytotoxic agents and the emerging field of cellular therapies in this group of patients.
Dr Chaganti is a consultant haematologist at University Hospitals Birmingham NHS Foundation Trust. He has a PhD in cancer studies from the University of Birmingham.
His research interest is Epstein–Barr virus (EBV) and lymphomas. His special interests are in haematologic malignancies, lymphomas and stem cell transplantation.

Friday Feb 21, 2025
Friday Feb 21, 2025

Friday Feb 21, 2025
Friday Feb 21, 2025

Friday Feb 14, 2025
Friday Feb 14, 2025
Professor Martin Kaiser and Dr Matthew Jenner discuss the BSH Good Practice Paper for the diagnosis and initial treatment of transplant-eligible high-risk myeloma patients, published in July 2024.

Wednesday Nov 06, 2024
2024-11-06-Podcast-Keith_Gomez-Cancer_Associated_Venous-Thrombosis
Wednesday Nov 06, 2024
Wednesday Nov 06, 2024

Monday Oct 14, 2024
Monday Oct 14, 2024

Tuesday Sep 24, 2024
Diagnosis and management of smouldering myeloma
Tuesday Sep 24, 2024
Tuesday Sep 24, 2024
Professor Guy Pratt discusses the investigation, diagnosis and management of smouldering myeloma. This podcast is based on the British Society for Haematology’s 2024 Good Practice Paper, Diagnosis and management of smouldering myeloma.

Monday Jul 22, 2024
The assessment and management of bleeding risk prior to invasive procedures
Monday Jul 22, 2024
Monday Jul 22, 2024
This guidance update from the BSH is focussed primarily on non-surgical invasive procedures, simply termed ‘procedures’ in this document, with the primary objective of giving pragmatic advice where evidence is limited. This guidance also aims to reduce unnecessary laboratory testing, inappropriate use of blood products and unnecessary delays in therapeutic procedures.1 It should be read in conjunction with the Interventional Radiology (IR) procedure bleeding risk guidance produced by the British Society of Interventional Radiology (BSIR) and the BSH.2 Recommendations are predominantly based on evidence from adult patients and therefore may not be applicable to neonates or very young children.